Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
PLG potentiates the action of levodopa in 6-OH-DA-treated rats. PLG plus levodopa is more effective than levodopa alone. PLG-treated rats have a decreased concentration of Leu-enkephalin in the caudate nucleus as compared with the control. Preliminary results of using PLG (400 mg/day) for 10 days for treating PD are satisfactory. The mode of action of PLG with relation to dopamine-enkephalin interaction is discussed.
D000368:Aged; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D004743:Enkephalin, Leucine / Q000378:metabolism; D005260:Female; D006801:Humans; D006892:Hydroxydopamines / Q000633:toxicity; D007980:Levodopa / Q000627:therapeutic use; D009075:MSH Release-Inhibiting Hormone / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016627:Oxidopamine; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects
D000978:Antiparkinson Agents; D006892:Hydroxydopamines; D007980:Levodopa; D004743:Enkephalin, Leucine; D016627:Oxidopamine; D009075:MSH Release-Inhibiting Hormone